Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Roche's RG-6237?
RG-6237 is a monoclonal antibody commercialized by Roche, with a leading Phase III program in Spinal Muscular Atrophy (SMA). According...
Data Insights
RG-6237 by F. Hoffmann-La Roche for Obesity: Likelihood of Approval
RG-6237 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Obesity. According to GlobalData, Phase...